Drug intelligence / Profile preview

Tezhixing

Development stage: Preclinical
Lead developer: Shanghai Tonglian Pharmaceutical

Overview

Tezhixing is a pharmaceutical drug currently being investigated in an exploratory clinical study for its role in treating solid tumors complicated by infection. It is being studied both as a monotherapy and in combination with antibiotics such as Colimycin and Meiping. The clinical trial is being conducted by Shanghai Tonglian Pharmaceutical Co., Ltd and Shanghai Sixth People's Hospital.

Other names: 特治星

Beyond the preview

Go deeper on Tezhixing.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tezhixing.

Explore the full profile